Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8915 results

  1. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  2. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  3. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

    Withdrawn advice

  4. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

    Withdrawn advice

  5. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  6. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Withdrawn advice

  7. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Withdrawn advice

  8. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  9. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  10. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Withdrawn advice

  11. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  12. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  13. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  14. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  15. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice